leadf
logo-loader
viewMaxCyte Inc

MaxCyte expands phase I cancer trial to two further centres

Researchers at Massachusetts General Hospital and Hackensack University Medical Center will join teams at the National Cancer Institute and Washington University at St Louis in helping evaluate the cell therapy

MaxCyte Inc -

MaxCyte Inc (LON:MXCT) has said its CARMA Cell Therapies research arm is expanding the phase I trial of its promising cancer immunotherapy, MCY-M11.

Doctors and scientists at Massachusetts General Hospital and Hackensack University Medical Center will join teams at the National Cancer Institute and Washington University at St Louis in helping evaluate the cell therapy.

The treatment will be used to combat difficult relapsed or refractory ovarian cancer and malignant peritoneal mesothelioma, which affects the lining of the abdomen.

READ: Emma Ulker's latest MaxCyte research 

The new teams will administer MCY-M11 via the peritoneum and patients will receive what is called a preconditioning regimen, consisting of a chemotherapy called cyclophosphamide.

Preconditioning is a widely used strategy to increase the efficacy of CAR-T treatment or to reduce its side effects.

“The addition of preconditioning regime in a separate cohort also provides a comparator to the MCY-M11 used as a single agent and will progress independently from the ongoing evaluation of MCY-M11 in the existing phase I cohort, and which is anticipated to be completed during 2020,” said Emma Ulker, analyst at Proactive Research.

MaxCyte expanded the phase I clinical assessment after unveiling “encouraging preliminary results” from the study in May.

Preliminary clinical data from the earlier patient groups are expected sometime in the second half of this year.

“The trial expansion highlights the potential for enhancing the breadth of data, efficacy and pace of recruitment into the phase I study of the lead CARMA candidate,” said Proactive analyst Ulker.

“This is central to the strategic planning for the CARMA Cell Therapies subsidiary, which is on track to secure independent funding in 2020.”

The shares were up 4.5% in early afternoon trade at 350p, valuing the business at £262mln.

---Adds analyst comment, video, link to the latest MaxCyte research---

Quick facts: MaxCyte Inc

Price: 410 GBX

AIM:MXCT
Market: AIM
Market Cap: £316.36 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MaxCyte Inc named herein, including the promotion by the Company of MaxCyte Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

MaxCyte Inc: Analyst talks expansion of its phase I clinical trial of MCY-M11

Proactive Research analyst Emma Ulker discusses the update this morning from MaxCyte Inc (LON:MXCT) on the expansion of its phase I clinical trial of MCY-M11 - its differentiated lead cell therapy candidate currently in first-in-human studies for advanced solid cancers. Ulker says the move is a...

on 18/8/20

2 min read